Agilent Technologies, Inc. (NYSE:A) SVP Sells $247,500.00 in Stock

Agilent Technologies, Inc. (NYSE:A) SVP Padraig Mcdonnell sold 1,500 shares of the stock in a transaction that occurred on Friday, November 19th. The shares were sold at an average price of $165.00, for a total value of $247,500.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of NYSE A opened at $152.97 on Thursday. The stock has a market cap of $46.31 billion, a PE ratio of 47.80, a PEG ratio of 2.67 and a beta of 0.98. The business has a fifty day moving average of $159.22 and a two-hundred day moving average of $154.31. Agilent Technologies, Inc. has a 52-week low of $112.47 and a 52-week high of $179.57. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.63 and a current ratio of 2.11.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Monday, November 22nd. The medical research company reported $1.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.17 by $0.04. The company had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.66 billion. Agilent Technologies had a return on equity of 26.12% and a net margin of 16.12%. The business’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the business earned $0.98 earnings per share. Analysts predict that Agilent Technologies, Inc. will post 4.31 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 26th. Shareholders of record on Tuesday, January 4th will be issued a dividend of $0.21 per share. The ex-dividend date of this dividend is Monday, January 3rd. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.19. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.55%. Agilent Technologies’s dividend payout ratio (DPR) is presently 24.38%.

Hedge funds and other institutional investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership raised its holdings in shares of Agilent Technologies by 155.9% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,978,462 shares of the medical research company’s stock valued at $626,727,000 after buying an additional 2,423,618 shares during the last quarter. Amundi bought a new position in shares of Agilent Technologies in the second quarter valued at about $334,124,000. Wellington Management Group LLP raised its holdings in shares of Agilent Technologies by 38.8% in the third quarter. Wellington Management Group LLP now owns 8,057,215 shares of the medical research company’s stock valued at $1,269,255,000 after buying an additional 2,250,500 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Agilent Technologies by 7.1% in the third quarter. BlackRock Inc. now owns 27,472,617 shares of the medical research company’s stock valued at $4,327,761,000 after buying an additional 1,820,330 shares during the last quarter. Finally, Two Sigma Advisers LP bought a new position in shares of Agilent Technologies in the third quarter valued at about $228,450,000.

Several equities research analysts have recently issued reports on A shares. Wells Fargo & Company raised their price objective on shares of Agilent Technologies from $150.00 to $180.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 18th. KeyCorp raised their price objective on shares of Agilent Technologies from $160.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 18th. Cowen raised their price objective on shares of Agilent Technologies from $180.00 to $187.00 and gave the stock an “outperform” rating in a research note on Tuesday. Citigroup raised their price objective on shares of Agilent Technologies from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, August 18th. Finally, Stifel Nicolaus lifted their price target on shares of Agilent Technologies from $162.00 to $169.00 and gave the stock a “hold” rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, Agilent Technologies has a consensus rating of “Buy” and an average price target of $151.75.

Agilent Technologies Company Profile

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets; Diagnostics and Genomics; and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.

Further Reading: When can a hold rating present a buying opportunity?

Insider Buying and Selling by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.